On “killers” working for OUR government, Trump spoke the truth—and our “free press” freaked out….
Here is the letter from OMB detailing the Obama Administration’s objections to the Intelligence Authorization Act passed by the House on February 26, 2010. (Thanks to Steven Aftergood at the Project on Government Secrecy at the Federation of American Scientists for posting it, and for his insightful discussion.)
An interesting study, published in JAMA Internal Medicine, was discussed yesterday on Medscape. Unsurprisingly, it appears we doctors overestimate the benefit of what we do, and underestimate the risk–by a lot. “Clinicians are likely to underestimate harms and overestimate benefits of tests and treatments, according to the results of a review of 48 studies published online January…
From Jon Cohen and Martin Enserink, excerpts: For proprietary reasons, Lurie would not name the delay issues at each manufacturer, but said “one company was just really overoptimistic” in its delivery predictions to HHS. Initially, all of the makers of inactivated vaccine had trouble with the “potency assay” used to ensure that 15 micrograms of…
From NBC we learn Obama is going to give Americans more “confidence” in the NSA. “I’ll be proposing some self-restraint on the NSA and initiating some reforms that can give people some more confidence.” But lack of confidence is not the problem. Setting up a straw man to knock down “is an intentional misrepresentation of an opponent’s position, often used…
From the LA Times: … Rep. Rush D. Holt, a Democrat from New Jersey, the site of the postal box where the letters were mailed, reintroduced legislation Tuesday to establish an 11-member commission to study the anthrax attacks. “There are still questions to be answered and still lessons to be learned,” Holt said. “It would…
By the NYT’s Andrew Pollack; excerpts follow: On Thursday, the federal government ordered, on an emergency basis, 10,000 treatment courses of peramivir for its national stockpile. It is paying $22.5 million, or about $2,250 a patient. Shares of BioCryst rose nearly 13 percent, to $11.39. Peramivir is given intravenously, making it usable by hospitalized patients…